Journals / Retina-Vitreus / 2013 / Cilt: 21 - Sayı: 4

Factors associated with visual acuity after treatment of diabetic macular edema with ıntravitreal ranibizumab

İntravitreal ranibizumab enjeksiyonu uygulanan diabetik maküla ödemli olgularda görme keskinliğini etkileyen faktörler

Pages
269–273
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In addition, better visual acuity in patients who were on insulin treatment was related with better metabolic control.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: To evaluate the factors associated with visual acuity after treatment of diabetic macular edema with intravitreal ranibizumab.
📊
Key Findings & Data:Materials and Methods: 53 eyes of 37 patients with macular edema secondary to diabetic retinopathy were treated with 0.5 mg intravitreal ranibizumab injections and enrolled in the study.
💡
Conclusion & Impact:In addition, better visual acuity in patients who were on insulin treatment was related with better metabolic control.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Purpose: To evaluate the factors associated with visual acuity after treatment of diabetic macular edema with intravitreal ranibizumab. Materials and Methods: 53 eyes of 37 patients with macular edema secondary to diabetic retinopathy were treated with 0.5 mg intravitreal ranibizumab injections and enrolled in the study. These patients were evaluated with LogMAR visual acuity, biomicroscopy, optical coherence tomography results including central subfield thickness and ISOS/ELM injury, age, gender, diabetes mellitus type, treatment and chronicty, follow up time, number of injections, injection algorithm, type of macular edema, peripheral ischemia on fluorescein angiography (FA). Results: Mean follow-up was 12.7±8.3 months. The mean logMAR visual acuity and central subfield thickness were 0.74±0.77 and 425.6±186 μm before injections and 0.66±0.65 and 332 ±154 μm after the injections. Macular edema types were 41.5% sponge, 24.5% cystoid, 34% mixed. Serous macular detachment was seen at 20.8% of eyes with mixed type macular edema. Of 53 eyes, 52.8% had ISOS and 50.9% had ELM defect. Visual acuity was better in patients using insulin than oral antidiabetic drugs. There was no statistically significant difference with visual acuity and macular edema type. Conclusion: Central subfield thickness decreased and visual acuity increased after intravitreal injection of ranibizumab in cases of diabetic macular edema. The most important factor associated with worse visual acuity was persistence of ISOS/ELM defect. In addition, better visual acuity in patients who were on insulin treatment was related with better metabolic control.

Özet

Amaç: Diabetik maküla ödemi olan ve intravitreal ranibizumab enjeksiyonu uygulanan olgularda görme keskinliğini etki- leyen faktörlerin değerlendirilmesi. Gereç ve Yöntem: Diabetik maküla ödemi tanısı ile takip edilen 37 hastanın, intravitreal ranibizumab uygulanan 53 gözü çalışmaya dahil edildi. Yaş, cinsiyet, lateralite, diabet tipi ve süresi, diabet için alınan sistemik tedavi, eşlik eden hastalık- lar, takip süresi, enjeksiyon sayısı ve yapılış algoritması, enjeksiyon öncesi ve sonrası en iyi düzeltilmiş görme keskinlikleri (EDGK) not edildi. Spektral domain optik koherens tomografide (OKT) ödem tipi, enjeksiyon öncesi ve sonrası santral maküla kalınlığı (SMK), IS/OS ve ELM hasarı varlığı, ara yüzey bozukluğu, flöresein anjiografide (FA) perifer iskemisi değerlendirilerek bu faktörlerin görme keskinliği ile ilişkisi araştırıldı. Bulgular: Ortalama takip süresi 12.7±8.3 aydı. Enjeksiyon öncesi ortalama EDGK 0.74±0.77 logMAR, SMK 425.6±186 μm, son kontrolde EDGK 0.66±0.65 logMAR, SMK ise 332±154 μm idi. Spektral OKT’de olguların %41.5’inde sünger, %24.5’inde kistoid, %34’ünde mikst tipte ödem mevcuttu. Mikst tiplerin %20.8’inde seröz maküla dekolmanı eşlik etmekteydi. Olgula- rın %52.8’inde ISOS, %50.9’unda ELM hasarı saptandı. ISOS hasarı (p:0.00) ve ELM hasarı (p:0.00) ile son görme keskinliği arasında negatif korelasyon mevcuttu. İnsülin kullanan olgularda, oral antidiyabetik kullananlara göre son görme keskin- liği daha iyiydi (p:0.011). Sonuç: Diabetik maküla ödemli olgularda ranibizumab enjeksiyonu sonrası görme keskinliğinde artış ve SMK değerlerinde azalma olmaktadır. Son görme keskinliğini olumsuz etkileyen en önemli faktör OKT’de ELM ve ISOS hasarının olmasıdır. Ayrıca insülin kullanan hastalarda son görme keskinliğinin daha iyi olması bu hastalarda daha kontrollü kan şekeri dü- zeylerinin olması ile ilişkilidir.

🔖

Cite This Article

SELEN, F., DEMİREL, S., BATIOĞLU, F., ÖZMERT, E. (2013). Factors associated with visual acuity after treatment of diabetic macular edema with ıntravitreal ranibizumab. Retina-Vitreus, Cilt: 21 - Sayı: 4, 269–273. https://ajindex.com/articles/305116

References (14)

  1. Davidson J K. Clinical diabetes mellitus, diabetic eye disease. Thime Medica Publishers 1991;427-44
  2. The Eye. Fundamentals and Principles of Opthalmology, section II USA, American Academy of Opthalmology. LEO 2000;68-88
  3. UK Prospective Diabetes Study Group. Intensive blood-glu- cose control with sulponlyureas or insulin compared with con- ventional treatment and risk of complications in patients with type 2 diabetes: UKPDS 33. Lancet 1998;352:837-53
  4. Aiello Lp, Bursell SE, Clermont A, et al. Vascular endothe- lial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor. Diabetes 1997:46;1473-80
  5. Tolentino MJ, Millet JW, Gragoudas ES, et al. Intravenous in- jections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate. Ophthal- mology 1996;103:1820-2
  6. Brown DM, Regillo C. Anti-VEGF agents in the treatment of neovascular age-related macular degeneration: applying clini- cal trial results to the treatment of everyday patients. Am J Ophthalmol 2007;144:627-37
  7. Sadda SR, Stoller G, Boyer DS, et al. Anatomical benefit from ranibizumab treatment of predominantly classic neovascular age-related macular degeneration in the 2-year anchor study. Retina 2010;30:1390-9
  8. Mitchell P, Bandello F, Schmidt-Erfurth U, et al. The RE- STORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 2011;118:615-25
  9. Bresnick GH. Diabetic Maculopathy. A critical review highlight- ing diffuse macular edema. Ophthalmology 1983;90:1301-17
  10. Early Treatment Diabetic Retinopathy Research Group. Treat- ment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Early Treatment Diabetic Retinopa- thy Study Report Number 2. Ophthalmology 1987;94:761-4
  11. Lee CM, Olk RJ. Modified grid laser photocoagulation for dif- fuse diabetic macular edema. Long-term visual results. Oph- thalmology 1991;98:1594-602
  12. Golnaz Javey, Stephen G. Schwartz, et al. Emerging Pharma- cotherapies for Diabetic Macular Edema Experimental Diabe- tes Research Exp Diabetes Res 2012;54:8732
  13. Diabetic Retinopathy Clinical Research Network, “A random- ized trial comparing intravitreal triamcinolone acetonide and focal/grid laser photocoagulation for diabetic macular edema” Ophthalmology 2008;115:1447-49
  14. Elman MJ, Bressler NM, Qin H, et al. D